Cannabis-like synthetic compound delivers pain relief without addictive high, study finds
U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...
TD Cowen Remains a Buy on Vertex Pharmaceuticals (VRTX)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
Vertex Pharmaceuticals Leads 3 Value Stocks Offering Estimated Intrinsic Value
As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value ...
Investing Snacks13h
Palantir’s Stock Outlook: Analysts Split on Future Gains
Wedbush reaffirmed its “outperform” rating on Palantir Technologies, setting a $120 price target. Other analysts also ...
Investing Snacks13h
Vertex’s Journavx Poised for Big Outpatient Market Win
Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...
New drug blocks pain without causing addiction
Not a moment too soon: a drug is on the market that is effective in treating pain but is not addictive. Its generic name is suzetrigine — sold under the name Journavx — and it took 25 years to develop ...